Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5 or Framingham risk 20: post hoc analyses of the JUPITER trial requested by European health authorities

摘要

AimsOn the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce first major cardiovascular events among ‘high' global risk primary prevention patients defined either by Framingham risk score >20% or European systematic coronary risk evaluation (SCORE) ≥5%. However, as these are post hoc analyses, data describing these subgroups have not previously been available to the clinical community.